Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program

 Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program

Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program

Shots:

  • MD Anderson to receive payments based on the development and commercialization of Schrödinger’s WEE1 inhibitor compounds. Schrödinger to provide research funding & will unite with researchers in MD Anderson’s TRACTION platform to accelerate the development of new therapies
  • Schrödinger will be responsible to develop, manufacture & commercialize the products & gets the rights to all novel intellectual property
  • The focus of the collaboration is to accelerate & optimize the development of the WEE1 program through molecular biomarker-driven tumor type prioritization, patient stratification & validate biomarkers to predict response or resistance to a WEE1 inhibitor

Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post